8-K
filed June 8, 2026, 4:05 PM ET
ticker DYN
CIK 0001818794
other material
confidence high
sentiment neutral
materiality 0.15
Dyne Therapeutics shareholders approve doubling of authorized shares to 400M
Dyne Therapeutics, Inc.
- Shareholders elected David Lubner, Brian Posner, Jason Rhodes as Class III directors to three-year terms.
- Non-binding advisory vote approved executive compensation with ~98% of votes cast in favor.
- Authorized common stock doubled from 200M to 400M shares via charter amendment filed June 8.
- Charter amended to include officer exculpation provision limiting personal liability.
- Deloitte & Touche ratified as independent auditor for fiscal year ending December 31, 2026.
Key facts
Extracted from this filing and checked against the source text.
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Dyne Therapeutics, Inc. shareholders approved Ratification of Deloitte & Touche LLP as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-06-05 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2026-06-05
Exact text from the filing
The stockholders of the Company ratified the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Dyne Therapeutics, Inc. shareholders approved Non-binding advisory vote on executive compensation at the 2026-06-05 meeting.
- Proposal
- say on pay
- Outcome
- passed
- Meeting
- 2026-06-05
Exact text from the filing
The stockholders of the Company approved, on a non-binding advisory basis, the compensation of the Company’s named executive officers.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Dyne Therapeutics, Inc. shareholders approved Election of Class III directors at the 2026-06-05 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2026-06-05
Exact text from the filing
The stockholders of the Company elected David Lubner, Brian Posner and Jason Rhodes as Class III directors, each to serve for a three-year term expiring at the 2029 annual meeting of stockholders and until his respective successor has been duly elected and qualified.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Dyne Therapeutics, Inc. shareholders approved Approval of amendment to restated certificate of incorporation to increase authorized common stock from 200,000,000 to 400,000,000 shares at the 2026-06-05 meeting.
- Proposal
- charter amendment
- Outcome
- passed
- Meeting
- 2026-06-05
Exact text from the filing
The stockholders of the Company approved an amendment to the Company’s restated certificate of incorporation to increase the number of authorized shares of common stock from 200,000,000 shares to 400,000,000 shares (the “Authorized Shares Amendment”).
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Dyne Therapeutics, Inc. shareholders approved Approval of amendment to restated certificate of incorporation to provide for officer exculpation at the 2026-06-05 meeting.
- Proposal
- charter amendment
- Outcome
- passed
- Meeting
- 2026-06-05
Exact text from the filing
The stockholders of the Company approved an amendment to the Company’s restated certificate of incorporation to provide for officer exculpation (the “Officer Exculpation Amendment”).
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.